Apimeds Pharmaceuticals US Inc
APUS1.600USD
-0.140-8.05%
收盤 08/04, 16:00（美東）報價延遲15分鐘
12.65M總市值
虧損本益比TTM
關於 Apimeds Pharmaceuticals US Inc 公司
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
公司簡介
公司代碼APUS
公司名稱Apimeds Pharmaceuticals US Inc
上市日期May 09, 2025
CEOMr. Erik C. Emerson
員工數量2
證券類型Ordinary Share
年結日May 09
公司地址100 Matawan Road
城市MATAWAN
上市交易所NYSE American Consolidated
國家United States of America
郵編07747
電話18482015010
網址https://www.apimedsus.com/
公司代碼APUS
上市日期May 09, 2025
CEOMr. Erik C. Emerson
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hankil Yoon, Ph.D.
Dr. Hankil Yoon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Erick Frim
Mr. Erick Frim
Chief Financial Officer
Chief Financial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
持股股東
持股股東
佔比
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
股東類型
持股股東
佔比
Corporation
67.52%
Individual Investor
14.44%
Other
18.04%
機構持股
更新時間: 7月2日 週三
更新時間: 7月2日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
7
9.49M
81.96%
+7.39M
2025Q2
7
9.49M
81.96%
+7.39M
2025Q1
2
2.10M
18.15%
+2.10M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Apimeds, Inc.
4.39M
37.9%
+4.39M
--
May 12, 2025
Inscobee, Inc.
2.03M
17.52%
+544.04K
+36.65%
May 12, 2025
Dominus IB, Inc
800.00K
6.91%
+800.00K
--
May 09, 2025
Emerson (Erik C)
750.00K
6.48%
+750.00K
--
May 16, 2025
Koo (Jakap)
643.88K
5.56%
+28.50K
+4.63%
May 12, 2025
Seed 1 ho
600.00K
5.18%
+600.00K
--
May 09, 2025
Kim (Christopher)
277.50K
2.4%
+277.50K
--
May 16, 2025
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
